UK
Updated
Reviewed by Vidhi Upadhyay
UK Diabetes Prevention Programs Market Industry Trends and Forecast to 2034: Segmented by (Delivery, Payer, End User, Region) - Growth, Market Size, Future Prospects & Competitive Analysis, 2024-2034
UK · 2024–2034 · placeholder estimates
Values shown here are placeholder estimates, not researched figures. Researched 2024 historical, 2025 base-year and 2026–2034 forecast values are prepared with the full report.
Germany at $133.2 Mn.
Russia at 11.3% a year.Source: Acuitas Health Analytics. Full methods, sources and usage terms come with report purchase.
$100.1 Mn total, 2026–2034
| Year | Market size | Change that year | Since 2025 |
|---|---|---|---|
| 2024 (estimate) | $77.1 Mn | — | — |
| 2025 (base) | $84.2 Mn | +$7.0 Mn | — |
| 2026 (forecast) | $91.8 Mn | +$7.7 Mn | +9.1% |
| 2027 (forecast) | $100.2 Mn | +$8.4 Mn | +19% |
| 2028 (forecast) | $109.3 Mn | +$9.1 Mn | +29.9% |
| 2029 (forecast) | $119.2 Mn | +$9.9 Mn | +41.7% |
| 2030 (forecast) | $130.1 Mn | +$10.8 Mn | +54.6% |
| 2031 (forecast) | $141.9 Mn | +$11.8 Mn | +68.6% |
| 2032 (forecast) | $154.8 Mn | +$12.9 Mn | +84% |
| 2033 (forecast) | $168.9 Mn | +$14.1 Mn | +100.7% |
| 2034 (forecast) | $184.3 Mn | +$15.4 Mn | +119% |
Placeholder estimates. Each year is projected from our earlier market estimate and its CAGR. Researched values come with the full report.
US
$1.59 Bn
China
$353.8 Mn
Canada
$286.6 Mn
Japan
$244.6 Mn
Germany
$133.2 Mn
France
$107.0 Mn
Brazil
$90.8 Mn
UK (this report)
$84.2 Mn
Italy
$83.2 Mn
Ecuador
$76.4 Mn
India
$76.1 Mn
Spain
$67.9 Mn
Mexico
$62.1 Mn
Saudi Arabia
$62.2 Mn
Australia
$46.5 Mn
New Zealand
$40.2 Mn
Russia
$38.6 Mn
South Africa
$22.1 Mn
UAE
$17.8 Mn
Egypt
$10.3 Mn
Philippines
$9.4 Mn
Malaysia
$6.9 Mn
Hong Kong
$6.5 Mn
Thailand
$5.2 Mn
Singapore
$4.2 Mn
Kenya
$2.4 Mn
| Market size, 2025 | $84.2 Mn placeholder estimate |
|---|---|
| Forecast, 2034 | $184.3 Mn placeholder estimate |
| Growth (CAGR), 2025–2034 | 9.1% placeholder estimate |
| Years | 2024 historical · 2025 base year · 2026–2034 forecast |
| Segments | Delivery, payer and end user (see all) |
| Key players | Omada Health, Virta Health, Lark Health, WW International, Livongo Health (now part of Teladoc Health) (see all) |
| Active clinical trials | 7 in the UKSource: ClinicalTrials.gov, Studies recruiting, active or not yet recruiting, in the UK. Retrieved 12 Nov 2026. |
| Formats | PDF, PPTX, XLSX |
Sizes and growth here are placeholder estimates, not researched figures. Researched figures come with the full report.
Diabetes prevention programs help people with prediabetes lower their risk of type 2 diabetes through coaching on diet, activity and weight.
Key segments of the diabetes Prevention Programs market include delivery (In-Person Programs, Digital Programs and Hybrid Programs) and payer (Employers, Health Plans and Government).
Rising rates of obesity and type 2 diabetes, strong clinical results for new weight-loss medicines and growing acceptance of obesity as a chronic disease are driving the diabetes Prevention Programs market. Wider insurance coverage and more doctors trained in obesity care are adding to demand.
Oral formulations, combination therapies and use in heart, kidney and liver disease open new growth paths for the diabetes Prevention Programs market, especially in fast-growing emerging economies.
High treatment prices, limited reimbursement, supply shortages and side effects that lead some patients to stop treatment hold back the diabetes Prevention Programs market. Long-term safety data and lifestyle support are still needed for many patients.
The diabetes Prevention Programs market is moderately concentrated. Leading companies compete on product innovation, clinical evidence, pricing and geographic reach, and use partnerships and acquisitions to expand their portfolios.
The NHS gives care that is free at the point of use; in England, NICE advises which medicines and treatments the NHS should fund.[1] ClinicalTrials.gov lists 7 studies on Diabetes Prevention Programs that are recruiting, active or about to start in the UK.[2] Diabetes (adults): 8.8% of adults in 2022, the latest WHO figure for the UK.[3]
[1] National Institute for Health and Care Excellence. Checked 14 Nov 2026.
[2] ClinicalTrials.gov, Studies recruiting, active or not yet recruiting, in the UK. Retrieved 12 Nov 2026.
[3] WHO Global Health Observatory, Diabetes (adults, WHO) (% of adults). Retrieved 15 Nov 2026.
Licensing, quality standards and payment models from public and private payers shape how diabetes Prevention Programs services are delivered and paid for in UK. Government health programs and insurance coverage are key to access.
What doctors and scientists are doing in Diabetes Prevention Programs right now, from free public sources.
7 active trials in the UK
Recruiting, about to start, or running now.
8.8 % of adults
Diabetes (adults), UK, 2022 (WHO).
Compare every country on the Public Health DashboardSources: PubMed (US National Library of Medicine), ClinicalTrials.gov, WHO Global Health Observatory, World Bank. Fetched 15 Nov 2026. Papers and trials are found by search words, so the counts are a guide. Titles only; read each paper at its source.
[1] WHO Global Health Observatory, Diabetes (adults, WHO) (% of adults). Retrieved 14 Nov 2026.
[2] World Bank Open Data, Health spending per person (US$ per person). Retrieved 15 Nov 2026.
[3] World Bank Open Data, Doctors (per 1,000 people). Retrieved 14 Nov 2026.
From our blog
UK · 2 shared keywords
UK · 1 shared keyword
UK · 1 shared keyword
UK · 1 shared keyword
UK · 1 shared keyword
UK
Pharmaceuticals · UK
Medical Devices · UK
Medical Devices · UK
Medical Devices · UK
Medical Devices · UK
Pharmaceuticals · UK